NEWS

NEWS

Total 80

40
Press Release NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2021-06-08
39
Press Release NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
2021-05-25
38
Press Release NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting
2021-05-20
37
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Patients with High Grade Glioma
2021-03-30
36
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
2021-03-23
35
Press Release NeoImmuneTech Announces Closing of Initial Public Offering
2021-03-16
34
Press Release NeoImmuneTech Appoints Byung Ha Lee, Ph.D., as Chief Scientific Officer
2021-03-01
33
Press Release NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
2021-02-23
32
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2021-02-16
31
Press Release NeoImmuneTech Receives Notice of Approval from the Korea Exchange for Initial Public Offering on the KOSDAQ
2020-12-30

1 2 3 4 5 >>>